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Abstract
Background: Despite the prominent position of methotrexate (MTX) in Rheumatoid Arthiris (RA) therapeutics, its
real-world effectiveness may be influenced by a relative lack of tolerability or other side effects that physicians may
not be aware of but that are bothersome to patients.
The aim of this study is to identify suboptimal patient experience with MTX and to raise awareness for clinicians to
identify opportunities to mitigate bothersome symptoms and side effects and optimize response to MTX.
Methods: We conducted a prospective, cross-sectional, online survey among RA patients who were members of
Creakyjoints, a large arthritis patient community. Eligible participants must have recently initiated a new biologic,
subcutaneous (SQ) MTX, or oral MTX in the last 12 months and were uniquely assigned to one of these 3 groups.
Descriptive statistics were used to compare patient-reported side effects and tolerability related to MTX use in the 3
medication groups (SQ MTX, oral MTX, and biologic).
Results: A total of 382 (85 %) of 448 eligible patients completed the survey and were grouped as: biologic (n = 218), SQ
MTX (n= 49), and oral MTX (n = 115). Demographics were mean standard deviation (SD) age 48 (10) years, 92 % white,
91 % women. Symptoms significantly more prevalent in the SQ and oral MTX groups included diarrhea, fatigue, malaise,
and hair loss. Injection related pain was lower with SQ MTX compared to SQ biologics. Out of a total of 8 potential
symptoms and side effects examined, higher dose MTX (> = 20 mg/week) was associated with a 2.26 (1.25–4.09) greater
likelihood of more side effects referent to < =10 mg/week.
Conclusion: Results from this real-world RA patient cohort suggest that MTX is accompanied by many patient-reported
side effects and tolerability problems that may be under-recognized by physicians. These may impact both treatment
satisfaction and medication adherence.
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Background
Methotrexate (MTX) has been a valuable treatment for
rheumatoid arthritis (RA) for more than 30 years, and it
remains the anchor drug for RA therapy [1–3]. Although
MTX is generally safe, intolerability may be an important
cause of treatment discontinuation and often includes
gastrointestinal (GI) adverse events (AEs) [4–6]. While
most patients with RA in the United States receive MTX
orally [7], subcutaneous (SQ) administration is available
and may provide advantages in both efficacy and tolerabil-
ity [8–12].
Compared to oral MTX, SQ MTX has been shown to
provide increased bioavailability, which may confer greater
efficacy, particularly at higher doses in which oral MTX
bioavailability appears to plateau [11, 13]. SQ MTX has
been associated with a reduced frequency and intensity of
some GI AEs compared with oral MTX [14, 15] which
may improve treatment compliance and reduce MTX
* Correspondence: jrcurtis@uabmc.edu
1University of Alabama at Birmingham, 510 20th Street South, FOT 802,
Birmingham, AL 35294, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Curtis et al. BMC Musculoskeletal Disorders  (2016) 17:405 
DOI 10.1186/s12891-016-1254-x
discontinuation rates. However, the prevalence of symp-
toms and side effects associated with oral and SQ MTX
from data other than clinical trials has been characterized
in only a very limited fashion. In randomized controlled tri-
als (RCTs), for example, patients may report more severe
side effects as adverse events, yet fail to mention milder yet
meaningfully bothersome side effects (e.g. injection site
pain) because they are not systematically queried [16–18].
Given a limited experience from real-world settings to
assess the prevalence of patient-reported symptoms and
AEs that are associated with MTX or biologics, this
study evaluated these outcomes in RA patients who ini-
tiated oral MTX, SQ MTX, and biologic therapies. The
goal was to identify suboptimal patient experience with
MTX and to raise awareness for clinicians to identify op-
portunities to mitigate bothersome symptoms and side
effects and optimize response to MTX.
Methods
Cohort selection and eligibility
Patient data were collected through a compensated ($25)
online survey disseminated by CreakyJoints®, a large arth-
ritis patient community. Recruitment was initiated on
March 31, 2014, and ended on November 16, 2014.
Eligible patients had self-reported RA and recently (within
the last 12 months) initiated a new biologic therapy, SQ
MTX, or oral MTX. Patients were uniquely assigned to 1
of 3 groups according to the following hierarchy: biologic
or novel small molecule (tofacitinib) (referred to hereafter
as the “biologic” arm), SQ MTX, and oral MTX. To avoid
selection bias, patients did not need to continue MTX to
be eligible for the survey and included in the two MTX
arms; for this reason, not all patients were current MTX
users at the time of the survey, and therefore reported
their experienced based upon their past use of MTX. Pa-
tients who initiated (for example) both a biologic and
MTX within the past 12 months were assigned to the bio-
logic cohort. All patients were asked to report symptoms
experienced in the relevant time frame, irrespective of per-
ceived causality from any particular medication. Patients
provided explicit informed consent to participate, and the
study was governed by the local University Institutional
Review Board at UAB.
Statistical analysis
The list of patient symptoms AEs were selected based on
content knowledge, with a focus on those perceived to be
common among oral or SQ MTX users. Similar questions
were asked of patients in the biologic group to provide
comparability. Patient characteristics by treatment group
and frequency of patient-reported AEs were compared
using descriptive statistics (chi square and t-tests). The se-
verity of symptoms was measured on an ordinal scale and
evaluated using the Cochran-Mantel-Haenszel test for
whether the row mean scores differed. The analysis was
done twice, the first time representing patients who said
that they did not experience the symptom as a “no” re-
sponse. The second method removed patients who said
that they did not experience the symptom and assessed
the severity of the symptom conditional on the patient
having experienced it. Among all patients who reported
that they were taking MTX (including those taking con-
comitant biologics), the incidence of 8 potentially MTX-
associated adverse events was evaluated as an ordinal out-
come (0-8 scale) and analyzed using ordinal logistic re-
gression with MTX dose as the independent variable, to
test the hypothesis that the number of symptoms was as-
sociated with higher MTX dose. Pain associated with the
administration of SQ MTX and biologics was reported on a
scale from 0 to 10, and mean scores were compared be-
tween patients who received etanercept, adalimumab, and
SQ MTX. Data were analyzed as complete cases only; those
who discontinued the survey prematurely (14.8 % of those
eligible) were not analyzed. All analyses were conducted in
SAS 9.4.
Results
Of 979 patients screened for the study, 448 (45.7 %)
were eligible and of these, 382 (85.2 %) completed the
survey in its entirety (Fig. 1). Based upon medications
initiated in the preceding 12 months, patients were
uniquely assigned to biologic therapy (n = 218), SQ
MTX (n = 49), or oral MTX (n = 115). Their characteris-
tics are described in Table 1. In the overall cohort, mean
(SD) age was 48.03 (10.21) years, 91 % were women, and
most (92 %) were White and from the U.S (90 %). Ap-










Fig. 1 Patient flow chart
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Table 1 Patient demographics
Overall Biologic therapies SQ MTX Oral MTX P-value
N = 382 n = 218 n = 49 n = 115
Age, mean (SD), y 48.03 (10.21) 46.98 (10.44) 49.46 (9.94) 49.43 (9.72) 0.67
Gender, % female 91.10 89.45 89.80 94.78 0.25
Race of participantsa
- American Indian 5 (1.3) 4 (1.8) 0 (0.0) 1 (0.9) 0.60
- Alaska Native 1 (0.3) 1 (0.5) 0 (0.0) 0 (0.0)
- Asian 3 (0.8) 1 (0.5) 1 (2.0) 1 (0.9)
- Native Hawaiian/other Pacific Islander 1 (0.3) 1 (0.5) 0 (0.0) 0 (0.0)
- Black/African-American 7 (1.8) 6 (2.8) 1 (2.0) 0 (0.0)
- White 353 (92.4) 200 (91.7) 45 (91.8) 108 (93.9)
- Other 12 (3.1) 5 (2.3) 2 (4.1) 5 (4.4)
Ethnicity 0.17
- Hispanic or Latino 19 (5.0) 8 (3.7) 5 (10.2) 6 (5.2)
- Not Hispanic or Latino 360 (94.2) 209 (95.9) 43 (87.8) 108 (93.9)
- No answer 3 (0.8) 1 (0.5) 1 (2.0) 1 (0.9)
Participants Reside in the United States 343 (89.8) 197 (90.4) 43 (87.8) 103 (89.6) 0.85
Participants not from US 39 (10.2) 21 (9.6) 6 (12.2) 12 (10.4)
Participant employment status
- Full time 145 (38.0) 89 (40.8) 14 (28.6) 42 (36.5) 0.09
- Part time 40 (10.5) 18 (8.3) 9 (18.4) 13 (11.3)
- Retired 25 (6.5) 10 (4.6) 2 (4.1) 13 (11.3)
- Homemaker 37 (9.7) 18 (8.3) 4 (8.2) 15 (13.0)
- Student 12 (3.1) 8 (3.7) 1 (2.0) 3 (2.6)
- Disabled 123 (32.2) 75 (34.4) 19 (38.8) 29 (25.2)
Participant health insurance
- Medicare 52 (13.6) 29 (13.3) 7 (14.3) 16 (13.9) 0.54
- Medicare advantage 18 (4.7) 10 (4.6) 3 (6.1) 5 (4.4)
- Medicaid 28 (7.3) 18 (8.3) 0 (0.0) 10 (8.7)
- Tri-care/Military 5 (1.3) 5 (2.3) 0 (0.0) 0 (0.0)
- Commercial/Private 227 (59.4) 134 (61.5) 27 (55.1) 66 (57.4)
- Other/type 54 (14.1) 24 (11.0) 9 (18.4) 21 (18.3)
- None 34 (8.9) 20 (9.2) 6 (12.2) 8 (7.0)
Monthly co-payment (n) N/A
$0 47 (21.6) 2 (4.1) 15 (13.0) <0.0001
> $0–25 65 (29.8) 24 (49.0) 68 (59.1)
$25–$40 13 (6.0) 5 (10.2) 16 (13.9)
$40–80 23 (10.6) 0 (0.0) 6 (5.2)
$80–100 7 (3.2) 0 (0.0) 0 (0.0)
> $100 35 (16.1) 1 (2.1) 0 (0.0)
Don’t know 0 (0.0) 3 (6.1) 10 (8.7)
Missing 0 (0.0) 14 (28.6) 0 (0.0)
data are shown as n (%)
MTX methotrexate, SC subcutaneous, SD standard deviation
arace data are not mutually exclusive
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Table 2 Characteristics of patients that initiated biologics, oral and SQ MTX in the previous 12 monthsa
Biologic arm SQ MTX Oral MTX
N = 218 N = 49 N = 115










Frequency of MTX doses taken in last 4 weeks
4 doses 133 (61.0) 31 (63.3) 90 (78.3)
3 doses 7 (3.2) 1 (2.0) 9 (7.8)
2 doses 10 (4.6) 1 (2.0) 5 (4.4)
1 dose 1 (0.5) 2 (4.1) 2 (1.7)
0 dosesb 66 (30.3) 14 (28.6) 9 (7.8)
Not sure 1 (0.5) 0 (0.0) 0 (0.0)
Current MTX dose/week (mg)
None 95 (43.5) 14 (28.6) 9 (8.0)
Unknown 9 (4.1) 3 (6.1) 5 (4.4)
< = 10 36 (16.5) 8 (16.3) 22 (19.1)
> 10– < 20 42 (19.3) 7 (14.3) 44 (38.3)
> =20 28 (12.8) 17 (34.7) 44 (38.3)
Reasons that patients missed 1 or more MTX doses in the last 4 weeksc N/A
Forgot 1 (2.0) 0 (0.0)
Side effects 2 (4.1) 1 (0.9)
Pharmacy shortage 1 (2.0) 0 (0.0)
Doing well 1 (2.0) 1 (0.9)
Couldn’t afford 1 (2.0) 1 (0.9)
Other reasons 2 (4.1) 4 (3.5)
Willingness to pay for MTX N/A
$0 1 (2.0) 4 (3.5)
$10 7 (14.3) 13 (11.3)
Up to $25 19 (38.8) 34 (29.6)
$25–$40 5 (10.2) 26 (22.6)
$40–$80 2 (4.1) 6 (5.2)
Did injections hurt? N/A
No, never 55 (25.2) 11 (22.4)
Yes, rarely 34 (15.6) 14 (28.6)
Yes, sometime 76 (34.9) 15 (30.6)
Yes, often 53 (24.3) 9 (18.4)
Data shown as n (%)
n/a not asked
ato avoid selection bias, patients did not need to continue MTX to be included in the two MTX arms of the survey; for this reason, not all patients are current users
bThese are patients who reported that they were not currently taking MTX; they had discontinued at the time of the survey. However, some had recently
discontinued and thus the counts are not synonymous with the “Current Dose = none” response
cresponse among people who said they took only 1, 2, or 3 doses of MTX in the last 4 weeks
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disabled. Sixty percent of patients were commercially in-
sured. For all 3 treatment groups, the median monthly
drug copay for biologics and MTX was less than $25.
Demographics and other characteristics were similar be-
tween the 3 treatment groups.
As shown in Table 2, among the patients treated with
a biologic, the most commonly used agents were etaner-
cept (23 %) and adalimumab (24 %). Approximately 2/3
of the biologic users were concomitantly taking MTX,
and most of them reported good adherence, having
taken all 4 doses in the last 4 weeks. In the MTX arms,
28.6 % of SQ MTX users and 7.8 % of oral MTX users
reported that they were not still taking MTX.
Table 3 describes the frequency of side effects associ-
ated with biologics (stratified by concomitant methotrex-
ate use or not), SQ and oral MTX. Overall, the most
commonly reported AEs included diarrhea, fatigue, mal-
aise, mental fog, infection, and pain associated with in-
jection. Significant differences were found between the
groups in the reported incidence of diarrhea, fatigue,
malaise, mental fog, hair loss, and pain associated with
the injection. There were no significant differences be-
tween the two biologic subgroups (with and without
MTX) for any of the symptoms listed. Regarding
injection-related pain, 24 % of biologic treated patients
said that their injections hurt ‘often’ as compared to
18 % of SQ MTX users [not shown].
The severity of each of these patient-reported symp-
toms is described in Table 4. Differences between the 3
treatment groups largely mirrored the differences in in-
cidence described in Table 3. Conditional on patients
having each of these side effects, the severity of the spe-
cific side effect did not differ between treatments except
for mental fog for which severity was greater in both
MTX treatment groups compared to biologics. Among
the subgroup of patients currently receiving oral or SQ
MTX (with or without biologics), there was an associ-
ation between the dose of MTX and the number of side
effects experienced (Fig. 2). Patients receiving MTX at
weekly doses of < = 10 mg had fewer side effects than
those receiving higher doses. Results from the ordinal lo-
gistic regression showed that referent to < =10 mg/week,
patients receiving between 10 and 20 mg/week had a
1.57 (0.86–2.87) higher odds of a higher number of side
effects, and patients receiving > =20 mg/week had a 2.26
(1.25–4.09) higher odds of more side effects. Patient-
reported pain associated with SQ injections (Fig. 3) was
significantly greater for the administration of etanercept
Table 3 Patient-reported adverse events associated with biologic therapies (with and without methotrexate), subcutaneous
methotrexate, and oral methotrexate
AE, n (%) Biologics without MTX Biologics with MTX SQ MTX Oral MTX P value
n = 95 N = 123 n = 49 n = 115
Hair loss 10 (11) 11 (9) 17 (35) 35 (30) <0.0001
Diarrhea 2 (2) 6 (5) 6 (12) 26 (23) <0.0001
Vomiting 2 (2) 6 (5) 4 (8) 8 (7) 0.32
Nausea 11 (12) 17 (14) 27 (55) 39 (34) <0.0001
Other stomach problems 9 (10) 5 (4) 3 (6) 7 (6) 0.44
Fatigue 21 (22) 27 (22) 36 (73) 64 (56) <0.0001
Malaise 17 (18) 14 (11) 23 (47) 38 (33) <0.0001
Mental fog 14 (15) 19 (15) 18 (37) 33 (29) 0.0016
Infection 12 (13) 11 (9) 4 (8) 5 (4) 0.19
Any pain with injections 48a (89) 62a (84) 27 (55) N/A <0.0001
Side effect sumb <0.0001
0 67 (71) 91 (74) 5 (10) 36 (31)
1 4 (4) 7 (6) 9 (18) 12 (10)
2 4 (4) 7 (6) 7 (14) 19 (17)
3 10 (11) 5 (4) 12 (24) 17 (15)
4 6 (6) 6 (5) 8 (16) 14 (12)
> =5 4 (4) 7 (6) 8 (16) 17 (15)
P values reported from chi-square test
AE adverse event, MTX methotrexate, SQ subcutaneous
aOf 128 patients who received biologic therapies subcutaneously
bnumber of side effect of hair loss, diarrhea, vomiting, nausea, other stomach problems, fatigue, malaise, mental fog
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Table 4 Patient-reported severity of adverse events associated with biologic therapies, subcutaneous methotrexate, and oral methotrexate
Severity of hair loss
Therapy, n (%) N No Trivial Mild Moderate Marked Severe So severe I had to stop
Biologic therapies 218 197 (90) 2 (1) 4 (2) 12 (6) 0 (0) 3 (1) 0 (0)
SQ MTX 49 32 (65) 1 (2) 9 (18) 2 (4) 5 (10) 0 (0) 0 (0)
Oral MTX 115 80 (70) 2 (2) 10 (9) 8 (7) 13 (11) 2 (2) 0 (0)
P value for row mean score < 0.0001
P value for row mean score differs (excluding “No” responses) = 0.37
Severity of diarrhea
Therapy, n (%) N No Trivial Mild Moderate Marked Severe So severe I had to stop
Biologic therapies 218 210 (96) 1 (.5) 1 (.5) 3 (1.5) 1 (.5) 2 (1) 0 (0)
SQ MTX 49 43 (88) 0 3 (6) 0 (0) 2 (4) 1 (2) 0 (0)
Oral MTX 115 89 (77) 2 (2) 9 (8) 11 (10) 1 (1) 3 (2) 0 (0)
P value for row mean score < 0.0001
P value for row mean score differs (excluding “No” responses) = 0.50
Severity of vomiting
Therapy, n (%) N No Trivial Mild Moderate Marked Severe So severe I had to stop
Biologic therapies 218 210 (96) 0 5 (2) 1 (.5) 1 (.5) 1 (.5) 0 (0)
SQ MTX 49 45 (91) 2 (4) 1 (2) 0 1 (2) 0 (0) 0 (0)
Oral MTX 115 107 (93) 1 (1) 2 (1) 4 (4) 1 (1) 0 (0) 0 (0)
P value for row mean score = 0.63
P value for row mean score differs (excluding “No” responses) = 0.15
Severity of nausea
Therapy, n (%) N No Trivial Mild Moderate Marked Severe So severe I had to stop
Biologic therapies 218 190 (87) 0 (0) 7 (3) 11 (5) 6 (3) 2 (1) 2 (1)
SQ MTX 49 22 (45) 0 (0) 7 (14) 11 (22) 4 (8) 3 (6) 2 (4)
Oral MTX 115 76 (66) 12 (10) 17 (15) 10 (9) 0 (0) 0 (0) 0 (0)
P value for row mean score < 0.0001
P value for row mean score differs (excluding “No” responses) = 0.21
Severity of other stomach problems
Therapy, n (%) N No Trivial Mild Moderate Marked Severe So severe I had to stop
Biologic therapies 218 204 (94) 0 (0) 3 (1) 4 (2) 5 (2) 2 (1) 0 (0)
SQ MTX 49 46 (94) 0 (0) 1 (2) 0 0 2 (4) 0 (0)
Oral MTX 115 108 (94) 0 (0) 1 (1) 5 (4) 0 1 (1) 0 (0)
P value for row mean score = 0.87
P value for row mean score differs (excluding “No” responses) = 0.50
Severity of fatigue
Therapy, n (%) N No Trivial Mild Moderate Marked Severe So severe I had to stop
Biologic therapies 218 170 (78) 1 (.5) 5 (2) 17 (8) 10 (4.5) 13 (6) 2 (1)
SQ MTX 49 13 (27) 0 4 (8) 16 (33) 5 (10) 10 (20) 1 (2)
Oral MTX 115 51 (44) 0 5 (4) 25 (22) 23 (20) 10 (9) 1 (1)
P value for row mean score = <0.0001
P value for row mean score differs (excluding “No” responses) = 0.90
Severity of malaise
Therapy, n (%) N No Trivial Mild Moderate Marked Severe So severe I had to stop
Biologic therapies 218 187 (86) 2 (1) 3 (1) 13 (6) 9 (4) 3 (1) 1 (1)
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and adalimumab compared with SQ MTX (P < 0.0001
for each), but etanercept and adalimumab were not dif-
ferent from other another.
Discussion
This study is among the few that assessed the frequency
of patient symptoms and side effects associated with ini-
tiation of SQ and oral methotrexate in a real-world set-
ting. We found several significant differences in the
frequency of several of these compared to biologic ther-
apy. For example, between one-third and one-half of pa-
tients receiving either formulation of MTX reported
malaise and between half and three-quarters reported fa-
tigue, a much greater proportion than in the biologic
users (22 %). At least some hair loss was reported by ap-
proximately 30 % of patients in both MTX arms. The
patient-reported prevalence of diarrhea was lower
among patients receiving SQ MTX than among those
receiving oral MTX, although nausea was more frequent
with SQ MTX. Rates of mental fog and hair loss also
were highest among patients receiving SQ MTX, and
the greater prevalence of these symptoms may possibly
reflect higher drug levels. Both the incidence and the
magnitude of injection pain associated with SQ MTX
was significantly lower than that associated with etaner-
cept and adalimumab.
Results from clinical trials of RA patients initiating
MTX generally find lower rates of MTX- and biologic-
associated adverse events than found in our survey. For
example, the TEAR trial found relatively low rates of
AEs associated with MTX monotherapy as given to early
RA patients for up to 2 years [19, 20], as did the
COMET trial [21]. However, observational studies,
which may have better generalizability for patients seen
in routine care, offer more heterogeneous results on this
topic. A single-center observational study of 248 U.S. pa-
tients found low rates of MTX discontinuation [4]. A
U.K. study conducted in two hospitals found that among
the patients changed from oral to SQ MTX, lack of effi-
cacy (51 %) and adverse events (44 %) were similarly
common, and high rates of subsequent persistence with
SQ MTX were observed (75 % at 2 years) [22]. In con-
trast, larger studies have generally found lower adher-
ence and poorer tolerability. For example, a large U.K.
cohort of 1257 patients (predominantly RA) found that
approximately 1/3 discontinued MTX, predominaly due
to GI tolerability [5]. This result is consistent with find-
ings from an older observational Norwegian study of
1648 patients that showed that 34 % of patients had dis-
continued at 2 years [23].
A number of studies have found better bioavailability
with SQ MTX compared to oral MTX [8, 24], which
may translate into improved efficacy among patients
who switch from oral to SQ MTX [13, 25–27]. However,
this effect may increase the rate of side effects associated
with more bioavailable MTX. Although not specifically
Table 4 Patient-reported severity of adverse events associated with biologic therapies, subcutaneous methotrexate, and oral methotrexate
(Continued)
SQ MTX 49 26 (53) 1 (2) 4 (8) 12 (24) 5 (10) 1 (2) 0 (0)
Oral MTX 115 77 (67) 0 12 (10) 20 (17) 5 (4) 1 (1) 0 (0)
P value for row mean score = <0.0001
P value for row mean score differs (excluding “No” responses) = 0.09
Severity of mental fog
Therapy, n (%) N No Trivial Mild Moderate Marked Severe So severe I had to stop
Biologic therapies 218 185 (85) 0 7 (3) 15 (7) 7 (3) 2 (1) 2 (1)
SQ MTX 49 31 (63) 0 4 (8) 11 (22) 3 (6) 0 0 (0)
Oral MTX 115 82 (71) 2 (2) 15 (13) 9 (8) 6 (5) 1 (1) 0 (0)
P value for row mean score = 0.01
P value for row mean score differs (excluding “No” responses) = 0.03
Severity of infection
Therapy, n (%) N No Trivial Mild Moderate Marked Severe So severe I had to stop
Biologic therapies 218 195 (95) 0 (0) 3 (1) 8 (1) 3 (1) 5 (2) 4 (2)
SQ MTX 49 45 (92) 0 (0) 1 (2) 2 (4) 1 (2) 0 (0) 0 (0)
Oral MTX 115 110 (96) 0 (0) 1 (1) 3 (2) 1 (1) 0 (0) 0 (0)
P value for row mean score = 0.06
P value for row mean score differs (excluding “No” responses) = 0.16
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addressed in our survey, the adverse event profile associ-
ated with MTX also has been shown to be influenced by
folate supplementation [28].
The frequency of pain associated with SQ injection
was greater for biologic users (84 %) compared to SQ
MTX users (55 %), as was the magnitude of pain. Injec-
tion pain might be further reduced by using an MTX
auto-injector, which has been rated by patients as easy
to use and nearly pain-free [10]. While patients generally
did not have very high out-of-pocket co-payments for
MTX, some patients receiving oral MTX expressed a
higher willingness to pay if MTX might have greater ef-
fectiveness or an improved side effect profile.
The strengths of our study include representation of a
patient population receiving care in routine settings.
Prior findings based predominantly on clinical trials of
biologics would presumably have much poorer
generalizability to a real-world experience. Of import-
ance in this study, patients needed to have started MTX
or biologics in the last 12 months but had no require-
ment that they remain on these therapies. This design
feature therefore avoided a potential selection bias if
only prevalent and ongoing MTX and biologic users
were eligible to participate. Were this the case, we pre-
sumably would have found a lower prevalence of various
symptoms and side effects that might have prompted
Fig. 2 Number of side effects* associated with current use of methotrexate, by dose. *Out of a maximum of 8 possible, as described in the first 8
rows of Table 3. Note: Analysis was restricted to patients who reported current MTX use and known dose (as described in Table 2)
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discontinuation. Additionally, we specifically prompted
for various symptoms and AEs of interest, which pa-
tients may feel more comfortable with reporting in a
survey, unlike clinical trials that passively ascertain such
symptoms only if reported as an AE. We note that pa-
tients reported on the prevalence and severity of some
symptoms (e.g. fatigue) that could either be drug related,
drug dose related (for MTX), and/or disease related.
Thus, the lower incidence of these symptoms in biologic
treated patients could reflect either effects of the drugs,
a lower median dose of MTX being used, or more effect-
ive control of disease-associated symptoms. We also
recognize that in the analysis of MTX dose and associ-
ated symptoms, confounding by disease severity may
have influenced our results. However, the comparison
with the results of the patients on biologic therapy
would somewhat argue against this, given that these pa-
tients presumably had more severe disease that war-
ranted biologic use.
Despite these strengths, several limitations of this ana-
lysis deserve mention. The survey population was a con-
venience sample, and people who are members of an
online patient community may be different than those
seen in routine medical care settings. For example, they
may have more severe, or more symptomatic RA, that
prompts them to seek help online. Also, patients had
self-reported RA, and while the positive predictive value
(PPV) of patient-reported RA is relatively low, the PPV
of patient reported RA among those who also report
DMARD or biologic use is appreciably higher [29]. We
acknowledge that medication use was self-reported and
was not externally confirmed. Importantly, our survey
was cross-sectional and patients’ responses were poten-
tially subject to recall bias. We also did not collect infor-
mation about comorbidities or RA disease activity, since
with a cross-sectional design, it would not be possible to
disentangle the relative contribution of these factors to
the outcomes we studied. Also, were not able to assess
improvement or worsening in patients who changed
medications. For example, the differential outcomes of
RA patients who experienced GI side effects (e.g. severe
nausea) while on oral MTX who then subsequently
changed to SQ MTX (who then experienced less nausea)
could not be ascertained since longitudinal data would
be required. Generating this type of data will be useful
to better characterize the benefits of changing from oral
MTX to SQ MTX or biologics in future studies. Add-
itionally, 29 % of patients in the SQ MTX arm had
already discontinued, a much higher proportion than in
the oral MTX arm (8 %), suggesting some potential bias
Fig. 3 Mean pain scores associated with subcutaneous MTX vs etanercept and adalimumab. *patients who said that they experienced no pain
with injection are included as having a 0 pain score. MTX, methotrexate
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in the sample with respect to the prevalence of side ef-
fects that could have prompted discontinuation. We also
recognize that most RA patients seldom start on SQ
MTX initially but rather ‘fail’ oral MTX and then switch,
suggesting the likelihood that more ill patients who need
greater treatment efficacy, or those with a higher burden
of GI side effects from oral therapy, probably were chan-
neled to SQ MTX. We also recognize that etanercept
and adalimumab-related injection site pain may differ
according to whether patients were using the pre-filled
syringe, the autoinjector pen, or the reconstituted lyoph-
ilized powder (for etanercept). The survey did not collect
this information, and was therefore not able to differen-
tiate between these different formulations. The survey
also did not ask about folate use, which has the potential
to mitigate MTX-associated side effects [30–32]. Finally,
although we examined a comparator of patients treated
with biologics, two-thirds of them were receiving con-
comitant MTX and their symptom profile likely reflected
the contribution of both biologic and MTX exposure.
However, these subgroups were separated in relevant
analyses (e.g. Table 3).
Conclusion
In conclusion, our results indicate that the prevalence of
MTX and biologic-associated symptoms and side effects
may be appreciably higher than prescribing information
for these agents or anecdotal experience might suggest.
Future longitudinal studies need to consider opportunities
to optimize use of MTX and evaluate the potential benefit
of switching from oral to SQ MTX in cases of intolerabil-
ity or inefficacy, which may delay patients’ progression to
biologic therapies, which may result in substantial cost
savings [33]. Further work to characterize strategies to
mitigate side effects associated with RA therapies (e.g.
higher doses of folate or folinic acid) may be useful to
maximize the benefits of MTX and other arthritis
medications.
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